Interleukin-12 and protamine inhibit angiogenesis and growth of c6 rat glioma: Synergistic effects and role of th2 cells İnterleukin-12 ve Protamin C6 Sıçan Gliomanın Anjiyogenezini ve Büyümesini İnhibe Eder: Sinerjik Etkiler ve Th2 Hücrelerinin Rolü

Creative Commons License

TURNA A., Kıran B., Ozar E., Turna H., Mercan C. A., Büyükpınarbaşılı N., ...Daha Fazla

Turkish Journal of Immunology, cilt.1, sa.3, ss.68-73, 2013 (SCI-Expanded, Scopus)

Özet

© 2013 Turkish Journal of Immunology. All rights reserved.Objectives: This study aims to investigate the anti-tumoral, anti-angiogenic and immunologic effects of interleukin-12 (IL-12) in combination with protamine in intracranially inoculated rat C6 glioma model. Material and methods: A 12-week-old 60 female Sprague-Dawley rats with a mean weight of 208±19 g were divided into six groups: C6 glioma cells were inoculated in group A; tumor in combination with recombinant IL-12 (rIL-12) 10 ng were inoculated intracranially in group B; rIL-12 10 ng intracranially with protamine 60 mg/kg subcutaneously were given to group C; protamine subcutaneously was given to group D; vehicle was given subcutaneously to group E; rIL-12 10 ng was subcutaneously given with protamine and tumor was inoculated in group F. Results: Intracranial rIL-12 and protamine exerted both anti-tumoral and anti-angiogenic effects (p=0.001). Intracranial rIL-12 administration significantly diminished peripheral blood Th2 cell ratio (p=0.03) and improved survival of the rats (p=0.001). Protamine monotherapy or in combination with IL-12 showed no immunologic alteration in T helper cell population. Conclusion: Recombinant IL-12 and protamine are effective against intracranially inoculated glioma, improve survival significantly as monotherapy or combination therapy and alter T helper cell cytokine secretion profile in favor of Th2 in rats.